503b bulk exclusion
5 Surprising Ways Semaglutide Exclusion Hits Independent Pharmacies
Independent pharmacies can expect more than a 40% surge in wholesale expenses for semaglutide after the FDA’s 503 B bulk exclusion, and the ripple effects touch every part of the business. The rule removes semaglutide, tirzepatide and liraglutide from the bulk list, forcing compounding operations to redesign supply chains